Rights and permissions
About this article
Cite this article
Recombinant EPO a no-go for avoiding transfusion-related adverse events. Pharmacoecon. Outcomes News 476, 9 (2005). https://doi.org/10.2165/00151234-200504760-00024
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200504760-00024